Clinical Characteristics Linked With Outcomes Among Patients Treated With Dabrafenib, Trametinib

Share this content:
Clinical characteristics, such as lactate dehydrogenase concentration and organ sites with metastases, are associated with survival outcomes.
Clinical characteristics, such as lactate dehydrogenase concentration and organ sites with metastases, are associated with survival outcomes.

Clinical characteristics, such as lactate dehydrogenase (LDH) concentration and organ sites with metastases, are associated with survival outcomes among patients with BRAFV600E-mutant or BRAFV600K-mutant advanced melanoma treated with dabrafenib plus trametinib, according to a study published in The Lancet Oncology.1

Researchers conducted a retrospective analysis of 617 patients with BRAFV600E-mutant or BRAFV600K-mutant metastatic melanoma who were treated with dabrafenib 150 mg twice daily along with trametinib 2 mg once daily.

Using univariate and multivariate analyses, the authors analyzed for factors during and after baseline based on known clinical and prognostic characteristics for melanoma to find any association with survival.

In total, 290 of the observed patients had died, and 396 had progression events.  Survival rates were consistent among individual trials and were as follows: median progression-free survival (PFS) was 11.1 months, median overall survival was 25.6 months, 1-year PFS rate was 48%, 1-year overall survival rate was 74%, 2-year PFS rate was 30%, and 2-year overall survival rate was 53%.

Patients who had normal LDH concentration and fewer than 3 organ sites that contained metastases had a 1-year PFS rate of 68% and 1-year overall survival rate of 90%, as well as a 2-year PFS rate of 46% and a 2-year overall survival rate of 75%.

RELATED: Binimetinib + Encorafenib Improves PFS vs Vemurafenib in Melanoma

In contrast, patients who had LDH concentrations that were “at least 2 times the upper limit of normal” had a 1-year PFS rate of 8% and a 1-year overall survival rate of 40%, as well as a 2-year PFS rate of 2% and a 2-year overall survival rate of 7%. 

Reference

  1. Long GV, Grob J, Nathan P, et al. Factors predictive of response, disease progression, and overall survival after dabrafenib and trametinib combination treatment: a pooled analysis of individual patient data from randomised trials. Lancet Oncol. 2016 Nov 15. doi: 10.1016/S1470-2045(16)30578-2 [Epub ahead of print]

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters